Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 July 2022 to Question 33936 on Radioligand Therapy, whether NHS England will undertake an expansion programme for radioligand therapy to help meet anticipated demand in the next two years.

NHS England reviews service provision when new treatments are recommended by the National Institute for Health and Care Excellence (NICE) through technology appraisals or due to the development of new clinical commissioning policy.

NICE is currently considering the use of lutetium vipivotide tetraxetan to treat certain types of prostate cancer after two or more treatments. Draft guidance published in October 2022 states that the treatment is not recommended and a final decision is expected in March 2023. If the treatment is recommended, this will inform any decisions on the provision of radioligand therapy, subject to demand and other access considerations.